Targets › CBL-B
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: the race on CBL-B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nurix Therapeutics | NX-1607 Cbl-b inhibitor | CBL-B | Phase 1 | Ovarian Cancer, Epithelial | Feb 2028 |
Ovarian Cancer, Epithelial (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.